Administration of the etonogestrel contraceptive implant on the day of mifepristone for medical abortion: a pilot study

Contraception. 2013 Nov;88(5):671-3. doi: 10.1016/j.contraception.2013.07.008. Epub 2013 Jul 29.

Abstract

Objective: We sought to determine satisfaction and continuation rates of the contraceptive implant when placed on the initial visit for first-trimester medical abortion.

Study design: In this pilot study, we placed the implant within 15 min of mifepristone administration. We assessed satisfaction with implant placement timing, 1-year implant continuation and abortion completion.

Results: We enrolled 20 participants. Sixteen (80%) returned for follow-up, and all had complete abortion. At 1 year, of 16 participants contacted, 14 (87.5%) were satisfied with implant insertion timing, and 14 (87.5%) continued the implant.

Conclusions: Initiation of the contraceptive implant on the initial visit for medical abortion resulted in high satisfaction and continuation rates.

Implications: This pilot study provides important groundwork for future larger studies to assess initiation of the contraceptive implant on the day of mifepristone for medical abortion.

Trial registration: ClinicalTrials.gov NCT01356927.

Keywords: First-trimester abortion; Long-acting reversible contraception.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abortifacient Agents, Steroidal*
  • Abortion, Therapeutic*
  • Adolescent
  • Adult
  • Boston
  • Contraception Behavior
  • Contraceptive Agents, Female / administration & dosage*
  • Contraceptive Agents, Female / adverse effects
  • Desogestrel / administration & dosage*
  • Desogestrel / adverse effects
  • Drug Implants
  • Female
  • Follow-Up Studies
  • Health Services Accessibility*
  • Humans
  • Middle Aged
  • Mifepristone*
  • Patient Acceptance of Health Care*
  • Patient Satisfaction
  • Pilot Projects
  • Pregnancy
  • Time Factors
  • Young Adult

Substances

  • Abortifacient Agents, Steroidal
  • Contraceptive Agents, Female
  • Drug Implants
  • etonogestrel
  • Mifepristone
  • Desogestrel

Associated data

  • ClinicalTrials.gov/NCT01356927